CMBA
FOLD

C.M. Bidwell & Associates’s Amicus Therapeutics FOLD Stock Holding History

C.M. Bidwell & Associates’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-215
Closed -$2.63K – 532
2022
Q4 		$2.63K Hold
215
– – ﹤0.01% 413
2022
Q3 		$2K Sell
215
-60
-22% -$669 ﹤0.01% 418
2022
Q2 		$3K Hold
275
– – ﹤0.01% 410
2022
Q1 		$3K Sell
275
-20,040
-99% -$188K ﹤0.01% 442
2021
Q4 		$235K Buy
+20,315
New +$226K 0.14% 132
2020
Q4 		– Sell
-11,820
Closed -$167K – 499
2020
Q3 		$167K Hold
11,820
– – 0.15% 138
2020
Q2 		$178K Hold
11,820
– – 0.16% 138
2020
Q1 		$109K Buy
+11,820
New +$112K 0.11% 160

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

C.M. Bidwell & Associates's FOLD Position: Q1 2023 in Review

C.M. Bidwell & Associates sold out of Amicus Therapeutics (FOLD) in Q1 2023, closing a stake of 215 shares — an estimated $2.63K sold.

C.M. Bidwell & Associates first reported a position in FOLD in Q1 2020 and held it in 8 quarters. The position peaked at $235K in Q4 2021. 226 funds tracked by Wall St. Rank hold FOLD as of Q1 2023.

  • C.M. Bidwell & Associates reported no remaining Amicus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 215 Amicus Therapeutics shares in Q1 2023, an estimated $2.63K.
  • C.M. Bidwell & Associates first reported a position in Amicus Therapeutics in Q1 2020 and held it in 8 quarters.
  • C.M. Bidwell & Associates's Amicus Therapeutics position peaked at $235K in Q4 2021.
  • 226 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2023, filed 12 May 2023.